News Summary

• FDA has cleared for marketing an innovative blood test with underlying technology invented at Washington University School of Medicine in St.
• The test, known as PrecivityAD2, was developed and validated by C2N Diagnostics, a WashU startup company.
• The blood test uses high-resolution mass spectrometry to measure the ratio of levels of amyloid (Aβ42 and 40) and two forms of tau protein (p-tau217 and total tau217) in the blood.